rs138213197
|
|
Prostate carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
The recurrent p.Gly84Glu germline mutation (G84E) in HOXB13 is consistently associated with prostate cancer (PCa), although the mechanisms underlying such linkage remain elusive.
|
30560549 |
2019 |
rs138213197
|
|
Prostate carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
The absolute PCa risk by age 85 for a male HOXB13 G84E carrier varied from 60% for those with no PCa family history to 98% for those with two relatives diagnosed at young ages, compared with an average risk of 15% for noncarriers.
|
30527799 |
2019 |
rs138213197
|
|
Prostate carcinoma
|
T |
0.800 |
GeneticVariation
|
GWASCAT |
Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci.
|
29892016 |
2018 |
rs138213197
|
|
Prostate carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
While there was a trend toward an earlier age at diagnosis, overall the clinicopathologic features of PCa were not significantly different in G84E carriers and non-carriers.
|
29181843 |
2018 |
rs138213197
|
|
Prostate carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Interplay of <i>HOXB13</i> (G84E) and <i>CIP2A</i> (R229Q) variants results in highest observed inherited prostate cancer risk (OR, 21.1; <i>P</i> = 0.000024).
|
30181389 |
2018 |
rs138213197
|
|
Prostate carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
We identified 101 heterozygous carriers of G84E who underwent radical prostatectomy for prostate cancer between 1985 and 2011 and matched these men by race, age and tumor grade to 99 HOXB13 wild-type controls.
|
28186998 |
2017 |
rs138213197
|
|
Prostate carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
The HOXB13 G84E variant is associated with risk of prostate cancer (PCa), however the role this variant plays in P</span>Ca development is unknown.
|
29259341 |
2017 |
rs138213197
|
|
Prostate carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Our results indicated that significant increased PCa susceptibility was associated with rs138213197 compared with non-carriers (OR = 3.38, 95% CI: 2.45-4.66).
|
27626483 |
2016 |
rs138213197
|
|
Prostate carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
The prostate cancer risk allele p.G84E was identified in 18 (0.56%) of 3,187 cases and 16 (0.70%) of 2,300 controls (OR = 0.81, 95% CI = 0.41-1.59, P = 0.54).
|
27424772 |
2016 |
rs138213197
|
|
Prostate carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
The HOXB13 G84E mutation was identified in 0.49% of controls and in 2.51% of PCa cases.
|
26779768 |
2016 |
rs138213197
|
|
Prostate carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
The age-specific risk of prostate cancer among G84E mutation carriers was higher than among non-carriers.
|
25629170 |
2015 |
rs138213197
|
|
Prostate carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Our study confirms the association between the HOXB13 G84E variant and prostate cancer and suggests a novel association between G84E and leukemia and a suggestive association with bladder cancer.
|
26108461 |
2015 |
rs138213197
|
|
Prostate carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Then, 25 studies including 51,390 cases and 93,867 controls were included, and there was significant association between HOXB13 p.Gly84Glu mutation and overall cancer risk (OR = 2.872, 95% CI = 2.121-3.888, P < 0.001), particularly in prostate cancer (OR = 3.248, 95% CI = 2.313-4.560, P < 0.001), while no association was found in breast (OR = 1.424, 95% CI = 0.776-2.613, P = 0.253) and colorectal cancers (OR = 2.070, 95% CI = 0.485-8.841, P = 0.326).
|
26517352 |
2015 |
rs138213197
|
|
Prostate carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
The clinical importance of HOXB13 G84E in PrCa management has not been established.
|
25595936 |
2015 |
rs138213197
|
|
Prostate carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
While the HOXB13 G84E mutation may be rare, there may be a future role in genetic testing for this mutation after further studies of clinical utility in assessing prostate cancer risk.
|
24310616 |
2014 |
rs138213197
|
|
Prostate carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
HOXB13 G84E is prevalent in >1% of the Swedish population and is associated with a 3.5-fold increased risk of prostate cancer.
|
22841674 |
2014 |
rs138213197
|
|
Prostate carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Recent genetic epidemiologic studies identified a germline mutation in the homeobox transcription factor, HOXB13 G84E, which is associated with markedly increased risk for prostate cancer, particularly early-onset hereditary prostate cancer.
|
24722062 |
2014 |
rs138213197
|
|
Prostate carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
In the present study, carriers of the rare G84E variant in HOXB13 were both younger at the time of diagnosis and more likely to have a family history of prostate cancer compared with homozygotes for the wild-type allele.
|
24148311 |
2014 |
rs138213197
|
|
Prostate carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
G84E mutation in HOXB13 is firmly associated with prostate cancer risk: a meta-analysis.
|
24026887 |
2014 |
rs138213197
|
|
Prostate carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Additional genotyping, conditional regression and haplotype analyses indicated that the newly identified common variants tag a rare, partially correlated coding variant in the HOXB13 gene (G84E, rs138213197), which has been identified recently as a moderate penetrance PrCa susceptibility allele.
|
24550738 |
2014 |
rs138213197
|
|
Prostate carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
We performed a retrospective analysis of germline DNA samples from Ashkenazi Jewish men and a comparison group of non-Ashkenazi men treated for prostate cancer at our institution to determine the prevalence of HOXB13 G84E mutation in prostate cancer patients of Ashkenazi Jewish heritage, an ethnic group common to the New York City area.
|
23475555 |
2013 |
rs138213197
|
|
Prostate carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
There was a stronger association between the G84E variant and PC among men with no first-degree relative with PC (OR, 4.04; 95% CI, 1.12-14.51) compared to men with a family history of PC (OR, 1.49; 95% CI, 0.30-7.50; P = 0.36 for interaction).
|
23129385 |
2013 |
rs138213197
|
|
Prostate carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Testing for the G84E mutation in men with a positive family history may help distinguish those who merit more regular screening for prostate cancer.
|
23396964 |
2013 |
rs138213197
|
|
Prostate carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
A rare mutation G84E in HOXB13 was recently identified to be associated with prostate cancer (PCa) in Caucasians.
|
22718278 |
2013 |
rs138213197
|
|
Prostate carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
In conclusion, the G84E mutation of HOXB13, a relatively recent mutation that likely occurred in Northern Europe, significantly increases risk for PCa.
|
23393222 |
2013 |